# Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.

> **NCT06434753** · PHASE3 · RECRUITING · sponsor: **Hospital Universitari Vall d'Hebron Research Institute** · enrollment: 300 (estimated)

## Conditions studied

- Advanced Chronic Liver Disease
- Portal Hypertension
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Zinc Acexamate

## Key facts

- **NCT ID:** NCT06434753
- **Lead sponsor:** Hospital Universitari Vall d'Hebron Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-10-02
- **Primary completion:** 2026-03-02
- **Final completion:** 2026-03-02
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-06-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06434753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06434753, "Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06434753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*